Tatva Chintan Pharma Chem Limited will host a virtual one-to-one analyst meeting with Tamohara Investment Managers Pvt. Ltd. on July 30, 2026. The company disclosed the engagement schedule to the Bombay Stock Exchange and National Stock Exchange of India Limited on July 24, 2026, in compliance with market transparency norms. This interaction provides investors and financial institutions an opportunity to discuss the company’s operational and financial performance based on existing public disclosures.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ishwar Nayi, Company Secretary and Compliance Officer of Tatva Chintan Pharma Chem Limited, signed the intimation letter submitted to the exchanges. The company emphasized that the meeting schedule is subject to change if necessary.

Meeting Details

Information Scope

Tatva Chintan Pharma Chem Limited stated that it will refer only to publicly available information during the interaction. The company explicitly confirmed that no confidential or unpublished price sensitive information (UPSI) will be shared during the meeting. This ensures compliance with insider trading regulations while facilitating investor dialogue.

The details of the meeting and related disclosures are available on the company’s website at www.tatvachintan.com for public reference.

Tatva Chintan Pharma Chem Limited reported a 54.8% year-on-year increase in consolidated net profit to ₹159.81 million for the quarter ended 30 June 2026, driven by higher operational income. Total income from operations rose 43% to ₹1,671 million from ₹1,168.64 million in the same period last year. EBITDA stood at ₹323 million, representing an 86% growth year-on-year and a 15% improvement over the previous quarter. The company’s earnings per share (EPS) on a consolidated basis improved to ₹6.83 for the quarter, compared to ₹2.84 in the corresponding period of the previous year.

The Board of Directors approved the financial results during its meeting held on 17 July 2026. Additionally, the Board approved the establishment of a new greenfield manufacturing facility involving an investment of approximately ₹200 crores. The groundbreaking ceremony is scheduled for 20 July 2026. The proposed facility is designed as a future-ready manufacturing platform to support the commercialization of new products and provide capacity for the company's next phase of growth. Management expects the facility to generate revenue of around ₹300 crores at peak utilization, targeting an asset turnover ratio of 1.2x to 1.5x.

Segment-wise Performance

Phase Transfer Catalysts contributed ₹428 million in revenue, a 38% growth quarter-on-quarter and 47% increase year-on-year. Structure Directing Agents reported ₹578 million in revenue, reflecting a 10% growth quarter-on-quarter and a 47% increase year-on-year. Pharma & Agro Intermediates and Specialty Chemicals delivered ₹584 million in revenue, a 63% growth quarter-on-quarter and a 25% growth year-on-year. Electrolyte Salts achieved ₹63 million in revenue, recording a 52% decline sequentially and a growth of 76% year-on-year.

Consolidated Financial Results

Standalone Financial Results

The extract of the financial results was filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.